TORONTO -- (MARKET WIRE) -- February 13, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that its wholly owned subsidiary, Antigen Express, Inc., has received a Notice of Allowance in connection with US Patent Application No. 10/197,000 entitled Hybrid Peptides Modulate the Immune Response. The specific award covers fundamental aspects of the design and use of Ii-Key antigenic epitope hybrids in treating disease.
